Cargando…

Real‐world efficacy and safety outcomes of imatinib treatment in patients with chronic myeloid leukemia: An Australian experience

Tyrosine kinase inhibitors (TKI) have revolutionized the treatment of chronic myeloid leukemia (CML), but patients still experience treatment‐limiting toxicities or therapeutic failure. To investigate the real‐world use and outcomes of imatinib in patients with CML in Australia, a retrospective coho...

Descripción completa

Detalles Bibliográficos
Autores principales:	Adattini, Josephine A., Gross, Annette S., Wong Doo, Nicole, McLachlan, Andrew J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9475133/ https://www.ncbi.nlm.nih.gov/pubmed/36106342 http://dx.doi.org/10.1002/prp2.1005

Ejemplares similares

Insights into dasatinib use and outcomes in real-world patients with chronic myeloid leukemia
por: Adattini, Josephine A., et al.
Publicado: (2023)

Application of physiologically based pharmacokinetic modeling to understand real‐world outcomes in patients receiving imatinib for chronic myeloid leukemia
por: Adattini, Josephine A., et al.
Publicado: (2023)

Physiologically Based Pharmacokinetic Modeling Approaches for Patients With SARS‐CoV‐2 Infection: A Case Study With Imatinib
por: Adiwidjaja, Jeffry, et al.
Publicado: (2022)

Efficacy and safety of generic imatinib after switching from original imatinib in patients treated for chronic myeloid leukemia in the United States
por: Abou Dalle, Iman, et al.
Publicado: (2019)

Imatinib Efficacy, Safety and Resistance in Iranian Patients with Chronic Myeloid Leukemia: A Review of Literature
por: Amouei, Asiyeh, et al.
Publicado: (2021)

Imatinib in Chronic Myeloid Leukemia: an Overview
por: Sacha, Tomasz
Publicado: (2014)

Clinical efficacy and safety of imatinib in the management of Ph(+) chronic myeloid or acute lymphoblastic leukemia in Chinese patients
por: Zhu, Yu, et al.
Publicado: (2014)

Comparative study for the efficacy, safety and quality of life in patients of chronic myeloid leukemia treated with Imatinib or Hydroxyurea
por: Jain, Parveen, et al.
Publicado: (2013)

Real-world Imatinib Mesylate Treatment in Patients with Chronic Myeloid Leukemia: The Importance of Molecular Monitoring and the Early Molecular Response
por: Ferreira, Amanda Pifano Soares, et al.
Publicado: (2023)

Imatinib in chronic myeloid leukemia elderly patients
por: Gugliotta, Gabriele, et al.
Publicado: (2011)

Safety and Efficacy of Elective Switch from Nilotinib to Imatinib in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia
por: Ibrahim, Ali, et al.
Publicado: (2022)

Correction to: Real‑world imatinib mesylate treatment in patients with chronic myeloid leukemia: The importance of molecular monitoring and the early molecular response
por: Ferreira, Amanda Pifano Soares, et al.
Publicado: (2023)

Changes in bone metabolic parameters in children with chronic myeloid leukemia on imatinib treatment
por: Jaeger, Bernadette Anna Sophia, et al.
Publicado: (2012)

Long-term efficacy and safety of dasatinib in patients with chronic myeloid leukemia in accelerated phase who are resistant to or intolerant of imatinib
por: Ottmann, Oliver, et al.
Publicado: (2018)

Clinical efficacy and safety of imatinib treatment in children and adolescents with chronic myeloid leukemia: A single-center experience in China
por: Deng, Mengyue, et al.
Publicado: (2020)

Dasatinib in the treatment of imatinib refractory chronic myeloid leukemia
por: Ramchandren, Radhakrishnan, et al.
Publicado: (2009)

Monitoring imatinib plasma concentrations in chronic myeloid leukemia
por: Martins, Darlize Hübner, et al.
Publicado: (2011)

Targeted treatment of chronic myeloid leukemia: role of imatinib
por: Tamascar, Ila, et al.
Publicado: (2009)

Therapy of Chronic Myeloid Leukemia: Twilight of the Imatinib Era?
por: Trela, Ewelina, et al.
Publicado: (2014)

Renal tuberculosis in an imatinib-treated chronic myeloid leukemia
por: Chandra, Abhilash, et al.
Publicado: (2020)

Celecoxib suppresses autophagy and enhances cytotoxicity of imatinib in imatinib-resistant chronic myeloid leukemia cells
por: Lu, Ying, et al.
Publicado: (2016)

Efficacy and safety of tenofovir in chronic hepatitis B: Australian real world experience
por: Lovett, Grace C, et al.
Publicado: (2017)

Validation of the EUTOS Long-Term Survival Score in Chinese Chronic Myeloid Leukemia Patients Treated with Imatinib: A Multicenter Real-World Study
por: Yang, Xiawan, et al.
Publicado: (2020)

Peripheral neuropathy associated with imatinib therapy for chronic myeloid leukemia
por: Kavanagh, Simon, et al.
Publicado: (2018)

Perceptions of telehealth in real‐world oncological care: An exploration of matched patient‐ and clinician‐reported acceptability data from an Australian cancer centre
por: Collins, Anna, et al.
Publicado: (2022)

Efficacy and safety of dasatinib versus imatinib in the East Asian subpopulation of the DASISION trial of newly diagnosed chronic myeloid leukemia in chronic phase
por: Chuah, Charles T., et al.
Publicado: (2014)

Bosutinib efficacy and safety in chronic phase chronic myeloid leukemia after imatinib resistance or intolerance: Minimum 24-month follow-up
por: Gambacorti-Passerini, Carlo, et al.
Publicado: (2014)

Comparison of effectiveness and safety of Iranian-made vs. Indian-made imatinib in treatment of chronic myeloid leukemia
por: Moshfeghi, Kamran, et al.
Publicado: (2013)

Safety of bosutinib versus imatinib in the phase 3 BELA trial in newly diagnosed chronic phase chronic myeloid leukemia
por: Gambacorti-Passerini, Carlo, et al.
Publicado: (2014)

Proteome Changes Induced by Imatinib and Novel Imatinib Derivatives in K562 Human Chronic Myeloid Leukemia Cells
por: Arvaniti, Katerina, et al.
Publicado: (2014)

Curcumin Decreases Viability and Inhibits Proliferation of Imatinib-Sensitive and Imatinib-Resistant Chronic Myeloid Leukemia Cell Lines
por: Bilajac, Esma, et al.
Publicado: (2022)

Therapeutic options for chronic myeloid leukemia: focus on imatinib (Glivec(®), Gleevec™)
por: Henkes, Martin, et al.
Publicado: (2008)

Synergy between Proteasome Inhibitors and Imatinib Mesylate in Chronic Myeloid Leukemia
por: Hu, Zheng, et al.
Publicado: (2009)

An uneventful pregnancy and delivery, in a case with chronic myeloid leukemia on imatinib
por: Martin, Jovita, et al.
Publicado: (2011)

Imatinib resistance: a review of alternative inhibitors in chronic myeloid leukemia
por: Bitencourt, Roberta, et al.
Publicado: (2011)

Targeted treatment of imatinib-resistant chronic myeloid leukemia: Focus on dasatinib
por: Chuah, Charles, et al.
Publicado: (2009)

First-line treatment for chronic myeloid leukemia: dasatinib, nilotinib, or imatinib
por: Wei, Guoqing, et al.
Publicado: (2010)

Influence of Late Treatment on How Chronic Myeloid Leukemia Responds to Imatinib
por: Scerni, Ana Carolina Costa, et al.
Publicado: (2009)

Gynecomastia in a Boy with Chronic Myeloid Leukemia during Imatinib Therapy
por: Tavil, Betül, et al.
Publicado: (2013)

Promyelocytic Blastic Crisis in Chronic Myeloid Leukemia During Imatinib Treatment
por: Angriman, Federico, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_1s5rmpbb4l9qalin1jcg52eddb